BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26733610)

  • 1. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
    Vitale C; Falchi L; Ten Hacken E; Gao H; Shaim H; Van Roosbroeck K; Calin G; O'Brien S; Faderl S; Wang X; Wierda WG; Rezvani K; Reuben JM; Burger JA; Keating MJ; Ferrajoli A
    Clin Cancer Res; 2016 May; 22(10):2359-67. PubMed ID: 26733610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Costa LJ; Fanning SR; Stephenson J; Afrin LB; Kistner-Griffin E; Bentz TA; Stuart RK
    Leuk Lymphoma; 2015 Mar; 56(3):645-9. PubMed ID: 25130476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
    Chanan-Khan A; Miller KC; Musial L; Lawrence D; Padmanabhan S; Takeshita K; Porter CW; Goodrich DW; Bernstein ZP; Wallace P; Spaner D; Mohr A; Byrne C; Hernandez-Ilizaliturri F; Chrystal C; Starostik P; Czuczman MS
    J Clin Oncol; 2006 Dec; 24(34):5343-9. PubMed ID: 17088571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
    Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
    Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
    Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
    Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.
    Doubek M; Brychtova Y; Panovska A; Sebejova L; Stehlikova O; Chovancova J; Malcikova J; Smardova J; Plevova K; Volfova P; Trbusek M; Mraz M; Bakesova D; Trizuljak J; Hadrabova M; Obrtlikova P; Karban J; Smolej L; Oltova A; Jelinkova E; Pospisilova S; Mayer J
    Am J Hematol; 2015 May; 90(5):417-21. PubMed ID: 25645263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
    Ferrajoli A; Lee BN; Schlette EJ; O'Brien SM; Gao H; Wen S; Wierda WG; Estrov Z; Faderl S; Cohen EN; Li C; Reuben JM; Keating MJ
    Blood; 2008 Jun; 111(11):5291-7. PubMed ID: 18334676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.
    van Oers MH; Kuliczkowski K; Smolej L; Petrini M; Offner F; Grosicki S; Levin MD; Gupta I; Phillips J; Williams V; Manson S; Lisby S; Geisler C;
    Lancet Oncol; 2015 Oct; 16(13):1370-9. PubMed ID: 26377300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.
    Sher T; Miller KC; Lawrence D; Whitworth A; Hernandez-Ilizaliturri F; Czuczman MS; Miller A; Lawrence W; Bilgrami SA; Sood R; Wood MT; Block AW; Lee K; Chanan-Khan AA
    Leuk Lymphoma; 2010 Jan; 51(1):85-8. PubMed ID: 20055660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
    Witzig TE; Vose JM; Zinzani PL; Reeder CB; Buckstein R; Polikoff JA; Bouabdallah R; Haioun C; Tilly H; Guo P; Pietronigro D; Ervin-Haynes AL; Czuczman MS
    Ann Oncol; 2011 Jul; 22(7):1622-1627. PubMed ID: 21228334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
    Chavez JC; Piris-Villaespesa M; Dalia S; Powers J; Turba E; Nodzon L; Komrokji R; Sokol L; Locke FL; Lancet J; Sotomayor EM; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Res; 2016 Aug; 47():78-83. PubMed ID: 27285853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
    Wendtner CM; Hallek M; Fraser GA; Michallet AS; Hillmen P; Dürig J; Kalaycio M; Gribben JG; Stilgenbauer S; Buhler A; Kipps TJ; Purse B; Zhang J; De Bedout S; Mei J; Chanan-Khan A
    Leuk Lymphoma; 2016; 57(6):1291-9. PubMed ID: 26763349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.
    Flinn IW; Panayiotidis P; Afanasyev B; Janssens A; Grosicki S; Homenda W; Smolej L; Kuliczkowski K; Doubek M; Domnikova N; West SL; Chang CN; Barker AM; Gupta IV; Wright OJ; Offner F
    Am J Hematol; 2016 Sep; 91(9):900-6. PubMed ID: 27222473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
    Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
    J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
    Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
    Liang L; Zhao M; Zhu YC; Hu X; Yang LP; Liu H
    Ann Hematol; 2016 Sep; 95(9):1473-82. PubMed ID: 27329288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
    J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
    Spina F; Rezzonico F; Farina L; Corradini P
    Eur J Haematol; 2013 Apr; 90(4):340-4. PubMed ID: 23281656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.